Influence of Androgen Receptor Expression on the Survival Outcomes in Breast Cancer: A Meta-Analysis.
10.4048/jbc.2015.18.2.134
- Author:
Yoonseok KIM
1
;
Eunae JAE
;
Myunghee YOON
Author Information
1. Department of Surgery, Kosin University Gospel Hospital, Busan, Korea. mammomaster@naver.com
- Publication Type:Meta-Analysis ; Original Article
- Keywords:
Androgen receptors;
Breast neoplasms;
Disease-free survival;
Mortality
- MeSH:
Breast Neoplasms*;
Disease-Free Survival;
Female;
Humans;
Male;
Mortality;
Receptors, Androgen*;
Recurrence;
Triple Negative Breast Neoplasms
- From:Journal of Breast Cancer
2015;18(2):134-142
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: Despite the fact that the androgen receptor (AR) is known to be involved in the pathogenesis of breast cancer, its prognostic effect remains controversial. In this meta-analysis, we explored AR expression and its impact on survival outcomes in breast cancer. METHODS: We searched PubMed, EMBASE, Cochrane Library, ScienceDirect, SpringerLink, and Ovid databases and references of articles to identify studies reporting data until December 2013. Disease-free survival (DFS) and overall survival (OS) were analyzed by extracting the number of patients with recurrence and survival according to AR expression. RESULTS: There were 16 articles that met the criteria for inclusion in our meta-analysis. DFS and OS were significantly longer in patients with AR expression compared with patients without AR expression (odds ratio [OR], 0.60; 95% confidence interval [CI], 0.40-0.90; OR, 0.53; 95% CI, 0.38-0.73, respectively). In addition, hormone receptor (HR) positive patients had a longer DFS when AR was also expressed (OR, 0.63; 95% CI, 0.41-0.98). For patients with triple negative breast cancer (TNBC), AR expression was also associated with longer DFS and OS (OR, 0.44, 95% CI, 0.26-0.75; OR, 0.26, 95% CI, 0.12-0.55, respectively). Furthermore, AR expression was associated with a longer DFS and OS in women (OR, 0.42, 95% CI, 0.27-0.64; OR, 0.47, 95% CI, 0.38-0.59, respectively). However, in men, AR expression was associated with a worse DFS (OR, 6.00; 95% CI, 1.46-24.73). CONCLUSION: Expression of AR in breast cancer might be associated with better survival outcomes, especially in patients with HR-positive tumors and TNBC, and women. Based on this meta-analysis, we propose that AR expression might be related to prognostic features and contribute to clinical outcomes.
